News

ProMetic’s PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested. The objectives of this

The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of

Radient’s facility, commissioned in January, 2014, is a 20,000 square foot manufacturing plant centered around Radient’s patented, proprietary technology, Microwave Assisted Processing ("MAP"). With MAP, Radient produces natural

This opinion paves the way for Plandaí to immediately commence sales efforts in the United States. The Federal Food, Drug and Cosmetic Act requires that the US FDA

Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to

The trial is designed to assess the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy. NephroGenex CEO Pierre Legault said with the

Pharma Technology Focus’ digital magazine brings together the latest news from the pharmaceutical industry, as well as offering expert views and analysis from industry insiders to ensure the

Being developed for the treatment of several cancer indications including patients with recurrent glioblastoma, DNX-2401 is claimed to be the most potent and effective oncolytic virus delivered to

Prestalia, which is the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate, is indicated for the treatment of hypertension in the U.S. Perindopril is a